Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590720 · ClinicalTrials.gov registry record · Phase 2
A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma
A Phase 2 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00590720 is a Phase 2 study that was terminated before completion, run by MedImmune. The registered enrollment target is 11 participants.
The verdict
NCT00590720, a Phase 2 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety and tolerability of multiple fixed doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).
Interventions
- OTHER PLACEBO
- BIOLOGICAL MEDI528 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590720
The ClinicalTrials.gov registry entry for NCT00590720 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLACEBO is the first listed.
NCT00590720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590720 about?
NCT00590720 is a clinical study titled "A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma". The main objective of this study is to evaluate the safety and tolerability of multiple fixed doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).
What is the current status of trial NCT00590720?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2008-03. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00590720?
The interventions under investigation include: PLACEBO (OTHER), MEDI528 50 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00590720?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.